Arch Biopartners Inc. (ACHFF) Stock

About Arch Biopartners Inc.

Arch Biopartners Inc. is a biotechnology company focused on developing innovative technologies with significant medical and commercial potential. Their primary endeavor involves advancing Metablok, a lead drug candidate designed to treat or prevent dipeptidase-1 (DPEP-1) mediated inflammation in critical organs like the lungs, liver, and kidneys. This inflammation is a key factor in organ damage or failure, often seen in severe conditions such as sepsis and COVID-19. Additionally, the company is progressing with AB569, an investigational drug aimed at combating or deterring antibiotic-resistant bacterial infections, predominantly through topical application for wounds. Further expanding their portfolio, Arch Biopartners is developing Borg, a peptide-based technology that interfaces with solid surfaces to inhibit biofilm formation and reduce corrosion. Another distinct project is MetaMx, which consists of synthetic molecules specifically engineered to target brain tumor initiating cells and aggressive glioma cells. The company is headquartered in Toronto, Canada.

Arch Biopartners Inc. is headquartered in CA.

Arch Biopartners Inc. (ACHFF) stock trades at $0.61 with a market capitalization of $41.10M. The stock is valued at a negative price-to-earnings (P/E) ratio of -22.19, reflecting a net loss over the last twelve months, a negative price-to-book of -15.98, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.29 and $1.27, and currently trades 52.0% below its 52-week high.

On profitability, Arch Biopartners Inc. generates a return on equity (ROE) of 70.15% (not meaningful, as shareholders' equity is negative), return on capital employed of 66.73%.

Official website: www.archbiopartners.com